A Randomized Comparative Study of 24-and 6-Hour Infusion of Nafamostat Mesilate for the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis A Prospective Randomized Comparison Trial

摘要

Objectives: Although prolonged intravenous infusion (24 hours) of nafamostat mesilate is effective for the prevention of post/endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis, it requires hospitalization and is expensive. The aim of this study was to compare the efficacy of 24-versus 6-hour intravenous infusion of 20 mg nafamostat mesilate for the prevention of post-ERCP pancreatitis (PEP).